Adimab, Celgene collaborate for antibody discovery

Wednesday, August 21, 2013

Adimab, a technology company focuses on the discovery of fully human antibodies, has announced a multi-target discovery collaboration with Celgene of Summit, NJ. Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

[Read More]

Array BioPharma, Celgene announce collaboration

Wednesday, July 31, 2013

Array BioPharma will collaborate with New Jersey-based biopharmaceutical company Celgene for an Array-invented preclinical development program targeting a novel inflammation pathway.  Array will receive an up-front payment of $11 million and Celgene will have an exclusive option to license multiple clinical development candidates. Array is entitled to receive potential milestone payments of up to $376 million based upon achieving certain development, regulatory and sales objectives. Array is also entitled to receive royalties on net sales of all drugs and will retain all rights to the program if Celgene does not exercise its option.

[Read More]

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

[Read More]

MorphoSys, Celgene to jointly develop cancer program

Tuesday, July 2, 2013

Global biopharma companies MorphoSys and Celgene have agreed to jointly develop MOR202 globally and co-promote it in Europe. MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma and certain leukemias. It currently is being evaluated in a phase I/IIa trial in patients with relapsed/refractory myeloma. The companies will collaborate on the development of MOR202 in multiple myeloma and other indications and share costs.

[Read More]